var data={"title":"Pharmacology of antiviral drugs for influenza","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pharmacology of antiviral drugs for influenza</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 19, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two classes of antiviral drugs are available for the prevention and treatment of influenza:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The neuraminidase inhibitors, <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>, <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a>, and <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a>, which are active against both influenza A and influenza B.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The adamantanes, <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a>, which are only active against influenza A. Due to a marked increase in resistant isolates, these agents should <strong>not</strong> be used in the United States for influenza prophylaxis or treatment except in selected circumstances, which are discussed separately. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults#H20\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;, section on 'Choice of antiviral drug'</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults#H2855203998\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;, section on 'Choice of antiviral drug'</a>.)</p><p/><p><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> and <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> are the first-line agents for the prophylaxis and treatment of influenza. <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">Peramivir</a> can be used for the treatment of influenza in patients who cannot receive zanamivir or oseltamivir (eg, those who cannot tolerate inhaled or enteral agents).</p><p>The pharmacologic issues related to these drugs will be reviewed here. Their role in the prevention and treatment of influenza are discussed separately. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza\" class=\"medical medical_review\">&quot;Treatment and prevention of pandemic H1N1 influenza ('swine influenza')&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza\" class=\"medical medical_review\">&quot;Treatment and prevention of avian influenza&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">NEURAMINIDASE INHIBITORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a>, <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a>, and <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a> are structurally related drugs that have been approved by the US Food and Drug Administration for the prophylaxis and treatment of influenza.</p><p>In addition to their activity against current influenza A and influenza B strains, they are also active against the strain that caused the 1918 pandemic [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/1\" class=\"abstract_t\">1</a>] and against avian influenza A strains [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/2,3\" class=\"abstract_t\">2,3</a>]. (See <a href=\"topic.htm?path=epidemiology-transmission-and-pathogenesis-of-avian-influenza\" class=\"medical medical_review\">&quot;Epidemiology, transmission, and pathogenesis of avian influenza&quot;</a>.)</p><p>A 2003 meta-analysis of 17 treatment and 7 prevention trials concluded that neuraminidase inhibitors reduced the median duration of symptoms by approximately one day, and, depending upon the population studied and strategy adopted, reduced the odds of developing influenza by 70 to 90 percent [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Influenza hemagglutinin is a surface glycoprotein that binds to sialic acid residues on respiratory epithelial cell surface glycoproteins. This interaction is necessary for the initiation of infection. After viral replication, progeny virions are also bound to the host cell via sialic acid residues on cell surface glycoproteins. Neuraminidase-mediated removal of these sialic acid moieties permits release of progeny virions.</p><p>Neuraminidase inhibitors interfere with the release of progeny influenza virus from infected cells, thereby preventing new rounds of infection [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/5\" class=\"abstract_t\">5</a>]. <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a>, <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a>, and <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a> are sialic acid analogs that competitively inhibit neuraminidase on the surface of both influenza A and B.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Pharmacokinetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> is administered as an inhaled powder and has poor oral bioavailability. Approximately 15 percent of inhaled zanamivir is deposited in the bronchi and lungs, with the remainder staying in the oropharynx [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/6\" class=\"abstract_t\">6</a>]. It is highly concentrated in the respiratory tract [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/5\" class=\"abstract_t\">5</a>]. Excretion is primarily renal, but, given limited systemic bioavailability, there is no need to modify the dose in patients with renal insufficiency. The pulmonary half-life is 2.8 hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/7\" class=\"abstract_t\">7</a>]. Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/8\" class=\"abstract_t\">8</a>].</p><p><a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">Oseltamivir</a> phosphate is orally administered and is available as a capsule or powder for liquid suspension that is rapidly metabolized to the active form, oseltamivir carboxylate [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/9\" class=\"abstract_t\">9</a>]. When the powder for suspension is unavailable, a suspension can be compounded from capsules [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/10\" class=\"abstract_t\">10</a>]. A single 100 mg dose yields a peak plasma concentration of 250 <span class=\"nowrap\">mcg/L,</span> with an elimination half-life of approximately eight hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/11\" class=\"abstract_t\">11</a>]. Food does not affect peak concentration or overall systemic exposure. Elimination is primarily renal, and dose reduction is recommended for patients with reduced creatinine clearance.</p><p>In a small study of critically ill patients with 2009 to 2010 pandemic H1N1 influenza A infection, <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> was well absorbed [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/12\" class=\"abstract_t\">12</a>]. The usual dose of 75 mg twice daily resulted in plasma concentrations of the active carboxylate metabolite that were comparable with those observed among ambulatory patients in clinical trials.</p><p><a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">Peramivir</a> is administered as a single intravenous (IV) dose because it has a strong and prolonged affinity for influenza virus neuraminidase [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/13,14\" class=\"abstract_t\">13,14</a>]. The recommended dose of peramivir is 600 mg IV. Dosing must be adjusted in the setting of renal insufficiency.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Clinical use</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The use of the neuraminidase inhibitors for the prevention and treatment of influenza is discussed separately. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;</a> and <a href=\"topic.htm?path=influenza-and-pregnancy\" class=\"medical medical_review\">&quot;Influenza and pregnancy&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza\" class=\"medical medical_review\">&quot;Treatment and prevention of avian influenza&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> and <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> are generally well tolerated.</p><p class=\"headingAnchor\" id=\"H116594844\"><span class=\"h3\">Zanamivir</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following potential adverse effects should be considered before initiating <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The delivery system for <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> (inhaled dry powder) has raised concerns about use in patients with pulmonary disease, such as chronic obstructive pulmonary disease (COPD) or asthma. Respiratory distress associated with zanamivir has been reported in a patient presenting with an exacerbation of COPD [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/15\" class=\"abstract_t\">15</a>]. The safety of this drug in patients with severe COPD or asthma has not been established, and data from a placebo-controlled trial enrolling such patients suggest an increased risk of a substantial (greater than 20 percent) reduction in FEV1 in zanamivir recipients [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> is generally not recommended for individuals with underlying respiratory disease such as asthma or COPD [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/16,17\" class=\"abstract_t\">16,17</a>]. If it is used in such patients, a fast-acting bronchodilator should be readily available [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/17\" class=\"abstract_t\">17</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> inhalation powder is <strong>not</strong> recommended for use in nebulizers or mechanical ventilators since the lactose carrier can clog ventilator tubing [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/18,19\" class=\"abstract_t\">18,19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Concerns have also been raised about the ease of use of the Diskhaler device currently provided by the manufacturer to deliver the drug. In particular, older adult patients may have significant difficulty using the device correctly [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vasovagal-like episodes have been reported soon after the inhalation of <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> in postmarketing reports [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> should be avoided in patients with allergy to milk proteins, given the presence of the lactose carrier [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"headingAnchor\" id=\"H116594851\"><span class=\"h3\">Oseltamivir</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common toxicities reported with <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> have been nausea and vomiting, which occur in approximately 15 percent of recipients. These side effects are usually mild and limited to the first day or two of treatment [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/11,23-26\" class=\"abstract_t\">11,23-26</a>].</p><p>Postmarketing reports have identified rare but serious adverse events in patients with influenza who are taking neuraminidase inhibitors [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/27-30\" class=\"abstract_t\">27-30</a>]. These events include neuropsychiatric effects (delirium, hallucinations, confusion, abnormal behavior, convulsions, and encephalitis), death, and severe skin reactions (including toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/10\" class=\"abstract_t\">10</a>]. Most of the reports of neuropsychiatric events involved <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> and occurred in children in Japan, where the use of neuraminidase inhibitors is widespread [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/31\" class=\"abstract_t\">31</a>]. The events often had an abrupt onset and rapid resolution [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/29\" class=\"abstract_t\">29</a>]. A causal association between neuraminidase inhibitors and these events has not been established [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/32-36\" class=\"abstract_t\">32-36</a>]. Some of the adverse events may have been related to influenza infection rather than treatment [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/37-41\" class=\"abstract_t\">37-41</a>]. (See <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs#H7\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;, section on 'Rare adverse effects'</a>.)</p><p class=\"headingAnchor\" id=\"H961665629\"><span class=\"h3\">Peramivir</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diarrhea is the most common adverse effect reported in patients receiving <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a> (occurring in 8 percent of those receiving peramivir and 7 percent of those receiving placebo) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/14\" class=\"abstract_t\">14</a>]. Rare but serious adverse effects associated with peramivir include anaphylaxis and serious <span class=\"nowrap\">skin/hypersensitivity</span> reactions such as Stevens-Johnson syndrome and erythema multiforme.</p><p>As with <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a>, there have been postmarketing reports from Japan of delirium and abnormal behavior leading to injury in patients with influenza who were receiving <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a>. These events were reported primarily among children and often had an abrupt onset and rapid resolution. The contribution of peramivir to these events has not been established.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">ADAMANTANES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">Amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> are closely related adamantanes (also called M2 inhibitors). They are active only against influenza A. These drugs appear equally effective, although the widespread emergence of adamantane-resistant influenza A strains has limited their role in clinical practice. These agents should <strong>not</strong> be used for influenza prophylaxis or treatment except in selected circumstances. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults#H20\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;, section on 'Choice of antiviral drug'</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults#H2855203998\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;, section on 'Choice of antiviral drug'</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Mechanism of action</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">Amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> target the M2 protein of influenza A. This protein forms a proton channel in the viral membrane that is essential for efficient viral replication [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/42-44\" class=\"abstract_t\">42-44</a>].</p><p>Consistent with the importance of the M2 protein is the observation that resistance to <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> is mediated by single nucleotide changes involving the transmembrane portion of the molecule [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/45,46\" class=\"abstract_t\">45,46</a>]. Such mutations confer cross-resistance between the adamantanes [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/46\" class=\"abstract_t\">46</a>]. The rate of spontaneous mutations resulting in drug resistance in tissue culture is quite high, between 1:1000 and 1:10,000 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults#H12\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;, section on 'Adamantane resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Drug metabolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">Amantadine</a> is primarily excreted unchanged in the urine. In patients with an estimated creatinine clearance of less than 50 <span class=\"nowrap\">mL/min,</span> the daily dose should be reduced from the usual adult dose of 100 mg twice daily to 100 mg daily; a similar dose reduction is recommended for patients older than 65 years (<a href=\"image.htm?imageKey=ID%2F50350\" class=\"graphic graphic_table graphicRef50350 \">table 1</a>).</p><p><a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">Rimantadine</a> is extensively metabolized in the liver, and three hydroxylated metabolites have been described [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/47\" class=\"abstract_t\">47</a>]. Dose reduction from 100 mg twice daily to 100 mg daily is recommended for patients with severe hepatic dysfunction, renal failure (creatinine clearance &lt;10 <span class=\"nowrap\">mL/min),</span> and older adult patients (<a href=\"image.htm?imageKey=ID%2F50350\" class=\"graphic graphic_table graphicRef50350 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> are generally well tolerated, especially in younger, healthy adults. However, central nervous system (CNS) side effects are well described with amantadine, including anxiety, insomnia, impaired thinking, confusion, lightheadedness, and hallucinations. These side effects appear to be related to peak drug concentrations [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/48\" class=\"abstract_t\">48</a>] and are more common in older adult patients.</p><p>Studies in young adults report a discontinuation rate of 13 to 17 percent, largely attributable to CNS toxicity. Discontinuation was significantly higher than the 4 to 8 percent withdrawal rate with placebo [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/49,50\" class=\"abstract_t\">49,50</a>]. Similar CNS side effects have been described with <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> but at a considerably lower rate, resulting in withdrawal rates similar to that of placebo [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/49,51\" class=\"abstract_t\">49,51</a>].</p><p>Both <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> and <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> may be associated with an increased rate of seizure activity in patients with a history of epilepsy and should be used with caution in such individuals. Amantadine has anticholinergic effects that can cause dry mouth and mydriasis; as a result, it is contraindicated in patients with untreated angle closure glaucoma.</p><p class=\"headingAnchor\" id=\"H7239911\"><span class=\"h1\">RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although some instances of antiviral drug resistance among influenza viruses have occurred during antiviral therapy, some resistant influenza strains have spread widely in the absence of such drug pressure [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/52\" class=\"abstract_t\">52</a>]. Adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003, oseltamivir-resistant seasonal H1N1 influenza A viruses since 2007, and adamantane-resistant pandemic H1N1 influenza A viruses since 2009 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/52\" class=\"abstract_t\">52</a>]. Resistance to the adamantanes generally occurs more readily than resistance to the neuraminidase inhibitors [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/53\" class=\"abstract_t\">53</a>]. Antiviral drug resistance among influenza viruses is discussed in detail separately. (See <a href=\"topic.htm?path=antiviral-drug-resistance-among-seasonal-influenza-viruses\" class=\"medical medical_review\">&quot;Antiviral drug resistance among seasonal influenza viruses&quot;</a> and <a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs#H10\" class=\"medical medical_review\">&quot;Seasonal influenza in children: Prevention and treatment with antiviral drugs&quot;, section on 'Antiviral resistance'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza#H23\" class=\"medical medical_review\">&quot;Treatment and prevention of pandemic H1N1 influenza ('swine influenza')&quot;, section on 'Drug resistance'</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza#H5\" class=\"medical medical_review\">&quot;Treatment and prevention of avian influenza&quot;, section on 'Drug resistance'</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No trials have been performed to assess the safety or efficacy of antiviral drugs during pregnancy [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/54\" class=\"abstract_t\">54</a>]. All four approved drugs are US Food and Drug Administration pregnancy category C, indicating that their effects in pregnant women and fetuses have not been well defined.</p><p>Animal studies have shown no evidence of adverse outcomes in the offspring of animals exposed to the neuraminidase inhibitors during pregnancy [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/55-57\" class=\"abstract_t\">55-57</a>]. Among 61 women who took <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> during pregnancy, one case of trisomy 21 and one case of anencephaly were reported in their infants, although neither case was thought to be causally linked to drug exposure [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/56\" class=\"abstract_t\">56</a>]. Ten of the 61 pregnancies ended in abortion, six of which were therapeutic. Three pregnant women were exposed to <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> during clinical trials [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/55,57\" class=\"abstract_t\">55,57</a>]. Of these, one ended in spontaneous abortion, one in elective termination, and one resulted in a healthy infant.</p><p><a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">Amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> appear to be teratogenic and embryotoxic in animals [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/58\" class=\"abstract_t\">58</a>]. There are no adequate studies of either drug in pregnant women, but skeletal and cardiovascular abnormalities have been described in an infant exposed to amantadine during the first trimester of pregnancy [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/59\" class=\"abstract_t\">59</a>].</p><p>Levels exceeding 90 percent of the inhibitory concentration of <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> and its active metabolite, oseltamivir carboxylate, were detected in the cord blood of a neonate born to a woman with severe influenza who was being treated with oseltamivir 150 mg orally twice daily, which is twice the usual dose [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/60\" class=\"abstract_t\">60</a>]. In contrast, in a study that assessed the metabolism and transplacental transfer of oseltamivir in an ex vivo human placenta model, oseltamivir and its metabolite were only detected in the placentas in which extremely high doses of oseltamivir were administered (20- to 830-fold higher than therapeutic dosing) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/61\" class=\"abstract_t\">61</a>]. Further study is necessary to evaluate whether oseltamivir reaches substantial levels in the fetal circulation.</p><p>The indications for influenza prophylaxis and treatment in pregnant women are discussed separately. (See <a href=\"topic.htm?path=influenza-and-pregnancy\" class=\"medical medical_review\">&quot;Influenza and pregnancy&quot;</a> and <a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults#H19\" class=\"medical medical_review\">&quot;Prevention of seasonal influenza with antiviral drugs in adults&quot;, section on 'Pregnancy'</a> and <a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults#H2855204513\" class=\"medical medical_review\">&quot;Treatment of seasonal influenza in adults&quot;, section on 'Pregnancy'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The neuraminidase inhibitors, <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a>, <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a>, and <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">peramivir</a>, are active against influenza A and B. Zanamivir and oseltamivir are the first-line agents for the prophylaxis and treatment of influenza. Peramivir can be used for the treatment of influenza in patients who cannot receive zanamivir or oseltamivir (eg, those who cannot tolerate inhaled or enteral agents). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The adamantanes, <a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a>, are only active against influenza A. Because of a marked increase in resistant isolates, these agents should <strong>not</strong> be used for influenza prophylaxis or treatment except in selected circumstances. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neuraminidase inhibitors interfere with the release of progeny influenza virus from infected cells, thereby preventing new rounds of infection. (See <a href=\"#H3\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=amantadine-drug-information\" class=\"drug drug_general\">Amantadine</a> and <a href=\"topic.htm?path=rimantadine-drug-information\" class=\"drug drug_general\">rimantadine</a> target the M2 protein of influenza A, which forms a proton channel in the viral membrane that is essential for efficient viral replication. (See <a href=\"#H11\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">Zanamivir</a> is administered as an inhaled powder. <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">Oseltamivir</a> is orally administered and is available as a capsule or powder for liquid suspension. <a href=\"topic.htm?path=peramivir-drug-information\" class=\"drug drug_general\">Peramivir</a> is administered as a single intravenous dose. (See <a href=\"#H7\" class=\"local\">'Pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Both <a href=\"topic.htm?path=zanamivir-drug-information\" class=\"drug drug_general\">zanamivir</a> and <a href=\"topic.htm?path=oseltamivir-drug-information\" class=\"drug drug_general\">oseltamivir</a> are generally well tolerated. Zanamivir is not recommended for individuals with underlying respiratory disease such as asthma or chronic obstructive pulmonary disease. Cases of neuropsychiatric effects leading to fatal outcomes have been reported with oseltamivir, particularly in children in Japan, although the causal relationship remains unclear. (See <a href=\"#H9\" class=\"local\">'Adverse effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although some instances of antiviral drug resistance among influenza viruses have occurred in the setting of drug pressure (ie, during antiviral therapy), some resistant influenza strains have spread widely in the absence of drug pressure. As examples, adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003, oseltamivir-resistant seasonal H1N1 influenza A viruses since 2007, and adamantane-resistant pandemic H1N1 influenza A viruses since 2009. (See <a href=\"#H7239911\" class=\"local\">'Resistance'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/1\" class=\"nounderline abstract_t\">Tumpey TM, Garc&iacute;a-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2002; 99:13849.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/2\" class=\"nounderline abstract_t\">Leneva IA, Goloubeva O, Fenton RJ, et al. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001; 45:1216.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/3\" class=\"nounderline abstract_t\">Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/4\" class=\"nounderline abstract_t\">Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/5\" class=\"nounderline abstract_t\">Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/6\" class=\"nounderline abstract_t\">Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs 2002; 62:71.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/7\" class=\"nounderline abstract_t\">Peng AW, Milleri S, Stein DS. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother 2000; 44:1974.</a></li><li class=\"breakAll\">United States Food and Drug Administration. MedWatch Safety Alert. Relenza (zanamivir) inhalation powder. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm (Accessed on October 09, 2009).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/9\" class=\"nounderline abstract_t\">Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65 Suppl 2:ii5.</a></li><li class=\"breakAll\">Tamiflu (oseltamivir) prescribing information, revised October 2014. http://www.gene.com/download/pdf/tamiflu_prescribing.pdf (Accessed on November 25, 2014).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/11\" class=\"nounderline abstract_t\">Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999; 58:851.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/12\" class=\"nounderline abstract_t\">Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/13\" class=\"nounderline abstract_t\">Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568.</a></li><li class=\"breakAll\">RAPIVAB (peramivir injection), for intravenous use. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206426s003lbl.pdf (Accessed on August 20, 2016).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/15\" class=\"nounderline abstract_t\">Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342:661.</a></li><li class=\"breakAll\">Relenza prescribing information. http://us.gsk.com/products/assets/us_relenza.pdf (Accessed on October 08, 2008).</li><li class=\"breakAll\">http://www.fda.gov/cder/news/relenza/default.htm (Accessed on October 06, 2008).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/18\" class=\"nounderline abstract_t\">Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.</a></li><li class=\"breakAll\">US Centers for Disease Control and Prevention. Interim guidance on the use of influenza antiviral agents during the 2010-2011 influenza season http://www.cdc.ov/flu/professionals/antivirals/guidance/summary.htm (Accessed on December 28, 2010).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/20\" class=\"nounderline abstract_t\">Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322:577.</a></li><li class=\"breakAll\">Relenza (zanamivir) inhalation powder: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) &ndash; December 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm239917.htm (Accessed on February 10, 2011).</li><li class=\"breakAll\">Relenza (zanamivir) inhalation powder: safety labeling changes approved by the FDA Center for Drug Evaluation and Research (CDER) - December 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm239917.htm (Accessed on January 25, 2012).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/23\" class=\"nounderline abstract_t\">Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/24\" class=\"nounderline abstract_t\">Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/25\" class=\"nounderline abstract_t\">Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/26\" class=\"nounderline abstract_t\">Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336.</a></li><li class=\"breakAll\">U.S. Food and Drug Administration. Tamiflu pediatric adverse events: Questions and answers www.fda.gov/cder/drug/infopage/tamiflu/QA20051117.htm (Accessed on September 06, 2011).</li><li class=\"breakAll\">U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Tamiflu (oseltamivir phosphate). http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm (Accessed on September 06, 2011).</li><li class=\"breakAll\">U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Relenza (zanamivir). http://www.fda.gov/Safety/MedWatch/Safetyinformation/SafetyAlertsforHumanMedicalProducts/ucm094982.htm (Accessed on September 06, 2011).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/30\" class=\"nounderline abstract_t\">Hoffman KB, Demakas A, Erdman CB, et al. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012. BMJ 2013; 347:f4656.</a></li><li class=\"breakAll\">Pollack A. Childhood deaths in Japan bring new look at flu drug. New York Times, November 18, 2005.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/32\" class=\"nounderline abstract_t\">Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009; 21:79.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/33\" class=\"nounderline abstract_t\">Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010; 628:6.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/34\" class=\"nounderline abstract_t\">Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009; 53:4753.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/35\" class=\"nounderline abstract_t\">Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009; 63:596.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/36\" class=\"nounderline abstract_t\">Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31:1097.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/37\" class=\"nounderline abstract_t\">Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J 2008; 27:88.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/38\" class=\"nounderline abstract_t\">Hara K, Tanabe T, Nakano R, et al. Clinical characteristics of children with abnormal behaviors associated with influenza infection. J Jpn Pediatr Soc 2007; 111:38.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/39\" class=\"nounderline abstract_t\">Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36:111.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/40\" class=\"nounderline abstract_t\">Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J 2009; 28:647.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/41\" class=\"nounderline abstract_t\">Tanabe T, Hara K, Nakajima M, et al. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev 2010; 32:440.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/42\" class=\"nounderline abstract_t\">Bui M, Whittaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996; 70:8391.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/43\" class=\"nounderline abstract_t\">Tosteson MT, Pinto LH, Holsinger LJ, Lamb RA. Reconstitution of the influenza virus M2 ion channel in lipid bilayers. J Membr Biol 1994; 142:117.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/44\" class=\"nounderline abstract_t\">Takeda M, Pekosz A, Shuck K, et al. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 2002; 76:1391.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/45\" class=\"nounderline abstract_t\">Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/46\" class=\"nounderline abstract_t\">Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62:1508.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/47\" class=\"nounderline abstract_t\">Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother 1985; 28:216.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/48\" class=\"nounderline abstract_t\">Hirsch MS, Swartz MN. Drug therapy: antiviral agents (first of two parts). N Engl J Med 1980; 302:903.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/49\" class=\"nounderline abstract_t\">Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307:580.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/50\" class=\"nounderline abstract_t\">Pettersson RF, Hellstr&ouml;m PE, Penttinen K, et al. Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients. J Infect Dis 1980; 142:377.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/51\" class=\"nounderline abstract_t\">Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/52\" class=\"nounderline abstract_t\">Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/53\" class=\"nounderline abstract_t\">Dolin R. Resistance to neuraminidase inhibitors. Clin Infect Dis 2011; 52:438.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/54\" class=\"nounderline abstract_t\">Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/55\" class=\"nounderline abstract_t\">Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008; 14:95.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/56\" class=\"nounderline abstract_t\">Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1:i5.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/57\" class=\"nounderline abstract_t\">Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug Saf 1999; 21:267.</a></li><li class=\"breakAll\">Hayden FG. Antiviral drugs (other than antiretrovirals). In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier, Philadelphia 2005. p.514.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/59\" class=\"nounderline abstract_t\">Pandit PB, Chitayat D, Jefferies AL, et al. Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine. Reprod Toxicol 1994; 8:89.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/60\" class=\"nounderline abstract_t\">Meijer WJ, Bruinse HW, van den Broek MP, et al. Oseltamivir and its active metabolite cross the placenta at significant levels. Clin Infect Dis 2012; 54:1676.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-antiviral-drugs-for-influenza/abstract/61\" class=\"nounderline abstract_t\">Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol 2008; 2008:927574.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 7008 Version 22.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">NEURAMINIDASE INHIBITORS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Mechanism of action</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Pharmacokinetics</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Clinical use</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Adverse effects</a><ul><li><a href=\"#H116594844\" id=\"outline-link-H116594844\">- Zanamivir</a></li><li><a href=\"#H116594851\" id=\"outline-link-H116594851\">- Oseltamivir</a></li><li><a href=\"#H961665629\" id=\"outline-link-H961665629\">- Peramivir</a></li></ul></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">ADAMANTANES</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Mechanism of action</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Drug metabolism</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Adverse effects</a></li></ul></li><li><a href=\"#H7239911\" id=\"outline-link-H7239911\">RESISTANCE</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">PREGNANCY</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/7008|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/50350\" class=\"graphic graphic_table\">- Antivirals for influenza</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiviral-drug-resistance-among-seasonal-influenza-viruses\" class=\"medical medical_review\">Antiviral drug resistance among seasonal influenza viruses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-transmission-and-pathogenesis-of-avian-influenza\" class=\"medical medical_review\">Epidemiology, transmission, and pathogenesis of avian influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=influenza-and-pregnancy\" class=\"medical medical_review\">Influenza and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-seasonal-influenza-with-antiviral-drugs-in-adults\" class=\"medical medical_review\">Prevention of seasonal influenza with antiviral drugs in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seasonal-influenza-in-children-prevention-and-treatment-with-antiviral-drugs\" class=\"medical medical_review\">Seasonal influenza in children: Prevention and treatment with antiviral drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-avian-influenza\" class=\"medical medical_review\">Treatment and prevention of avian influenza</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-pandemic-h1n1-influenza-swine-influenza\" class=\"medical medical_review\">Treatment and prevention of pandemic H1N1 influenza ('swine influenza')</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-seasonal-influenza-in-adults\" class=\"medical medical_review\">Treatment of seasonal influenza in adults</a></li></ul></div></div>","javascript":null}